HMGB1 and neoplasm: Based on the potential association between HMGB1 and IDO, dual-target combination therapy with HMGB1 and IDO inhibitors may have better efficacy than tumor immunotherapy by inhibiting the activity of HMGB1 or IDO alone in the future.